Introduction
============

Noninvasive mechanical ventilation (NIMV) is effective in the treatment of patients with acute respiratory failure (ARF), as shown by controlled trials and meta-analysis ([@b5-copd-3-797]; [@b19-copd-3-797]; [@b25-copd-3-797]; [@b6-copd-3-797]; [@b21-copd-3-797]). In particular, NIMV proved to reduce the need of endotracheal intubation (ETI) ([@b2-copd-3-797]), to prevent ETI-associated pneumonia ([@b22-copd-3-797]; [@b7-copd-3-797]) and to decrease incidence of mortality compared to nonventilated patients ([@b17-copd-3-797]). During last decades NIMV use is continuously increasing ([@b7-copd-3-797]; [@b11-copd-3-797]), despite consensus documents established the rationale, and therefore also some limitations, to resort to NIMV in severe chronic obstructive lung disease (COPD), restrictive thoracic disorders, and nocturnal hypoventilation ([@b1-copd-3-797]). Nevertheless, NIMV may have some negative effects, for example the delay in using ETI when the respiratory conditions require such measure, an unsatisfactory outcome in patients with ARF due to severe community acquired pneumonia, and the risk to develop an aspiration pneumonia in patients with altered level of consciousness ([@b16-copd-3-797]; [@b23-copd-3-797]; [@b13-copd-3-797]).

A particular aspect is the outcome of NIMV in patients referring to an emergency department for ARF, who have a do-not-intubate (DNI) status because of elderly age or critical clinical conditions.

The aim of our study was the evaluation of the outcome of NIMV in a group of DNI elderly patients with hypercapnic ARF mainly due to COPD exacerbations.

Materials and methods
=====================

Patients
--------

Sixty-two patients, 30 males and 32 females, mean age 81 ± 4.8 years, range 79--91 years, with hypercapnic ARF (defined by PaCO~2~ \> 45 mm Hg and pH \< 7.35) ([@b29-copd-3-797]), hospitalized in the semi-intensive respiratory medicine unit of Vimercate Hospital, Milan, Italy were enrolled in the study. The inclusion criteria were age ≥75 years and a DNI status, as established by the intensive care physician, on the basis of advanced age and unfavorable clinical status. In Italy, exhaustive laws regulating the matter are currently lacking ([@b31-copd-3-797]). In 50 patients the underlying disease was severe COPD (stage 4 GOLD) in 50/62 patients, restrictive thoracic disorders (mainly severe kyphoscoliosis) in 7/62, and multiorgan failure in 5/62. All patients were already treated with long-term oxygen therapy (LTOT).

Methods
-------

Severity-of-illness classification was assessed by the Acute Physiology and Chronic Health Evaluation (APACHE) II ([@b18-copd-3-797]) and level of consciousness by the Glasgow Coma Score (GCS) ([@b28-copd-3-797]). Also PaO~2~/FiO~2~ ratio, PaCO~2~, pH, respiratory rate, heart rate, and blood pressure were measured. The main characteristics of subjects at baseline are reported in [Table 1](#t1-copd-3-797){ref-type="table"}.

All patients were under treatment with antibiotics, systemic corticosteroids, and bronchodilators. Those with multiorgan failure received the appropriate medical therapy.

NIMV was started in all patients already in the ER by the pneumologist on duty, and was continued in the semi-intensive respiratory medicine unit. NIMV was performed in 59 patients by pressure support, bilevel mode, and in 3 patients by volume support mode. Assisted controlled ventilation, setting a lower than spontaneous respiratory rate was used in conscious patients, while in the others, a controlled ventilation was used. Ventilators models Helia and Elisee 150 from Vivisol (Savigny Le Temple, France), with oronasal masks as interface, were used. Inspiratory (IPAP) and expiratory positive airway pressure (EPAP) were set according to patient's tolerance and blood gas parameters. All blood gas parameters were measured after one and 12 hours of continuous ventilation and at discharge.

The local Ethical Committee approved the procedures of the study, and patients or their relatives (depending on patient's clinical conditions) gave their verbal informed consent to NIMV.

Statistical analysis
--------------------

The results were expressed as mean ± SD. Mean values of considered parameters in patients successfully or unsuccessfully treated by NIMV were compared, for both intergroup and intragroup analysis, using ANOVA test. The one-way ANOVA was used to examine difference between groups at the enrolment and ANOVA with post-hoc analysis was used for repeated measures to test the trend of parameters for each group of patients, considering significant a p value \< 0.05. The small number of patients unsuccessfully treated prevented the comparison of categorical variables or the analysis of odds ratio by multivariate logistic regression.

Results
=======

Fifty-four/62 patients were successfully treated with NIMV, and discharged after a mean duration of hospitalization of 13.7 ± 5.1 days. In two patients significant changes in PaCO~2~ and pH values did not occur and, following the consent by their relatives, they were submitted to ETI, and one survived. In other six patients the treatment was unable to prevent death, which occurred after a mean of 9.9 ± 8.3 days of hospitalization. One subject, a 88-year-old male, died before the 12 hours assessment: he had an exacerbation in severe COPD, with a GCS score of 6, an APACHE score of 37, a PaO~2~/FiO~2~ ratio of 145, a PaCO~2~ of 96 mm Hg, and a pH of 6.9; after one hour of NIMV in bilevel mode, with IPAP 25 cm H~2~O and EPAP 7 cm H~2~O, the ratio PaO~2~/FiO~2~ moved to 103, the PaCO~2~ to 88 mm Hg, and the pH to 7.01. In the other six cases, death occurred for pneumonia (2/6), multiorgan failure (2/6), or ARF (2/6). The NIMV failure in the studied patients was 12.9%.

[Table 2](#t2-copd-3-797){ref-type="table"} reports the mean age, GCS and APACHE scores, and blood gas parameters at admission, and after both 1 and 12 hours in patients successfully or unsuccessfully treated. NIMV-nonresponders had a lower GCS and an higher APACHE score at baseline compared to NIMV-responders, while no differences in PaO~2~/FiO~2~, PaCO~2~ or pH were observed. NIMV-nonresponders had a significantly higher mean value of PaCO~2~ after 12 hours and a significantly lower pH value both after 1 and 12 hours. Intra-group comparison by ANOVA test with post-hoc analysis showed no significant change in PaO~2~/FiO~2~ and significant improvement in PaCO~2~ and pH (p \< 0.0001) in successfully treated, while no significant change for any parameter was found in unsuccessfully treated patients.

Thirty-five/54 patients who recovered after NIMV continued ventilation at home to control hypercapnia (PaCO~2~ = 52.5 mm Hg), while 19/54 needed only oxygen therapy (PaCO~2~ = 45.4 mm Hg) (p = 0.001).

Discussion
==========

The effectiveness of NIMV in ARF patients was clearly demonstrated by numerous randomized trials ([@b5-copd-3-797]; [@b19-copd-3-797]; Wisocki et al 1995; [@b3-copd-3-797]; [@b25-copd-3-797]; [@b6-copd-3-797]; [@b15-copd-3-797]). Studies regarding respiratory failure resulting from COPD exacerbations were included in a meta-analysis, that confirmed the favorable outcome of NIMV in such population ([@b21-copd-3-797]). However, the optimal settings and performances deriving from randomized trials could not be applicable in routine practice of NIMV, and therefore data deriving from observational studies are also important. A recent prospective observational study conducted in France on 524 patients reported a significantly better outcome in subjects with acute-on-chronic respiratory failure compared to those with acute *de novo* respiratory failure, showing a mortality rate of 20% and 41%, respectively ([@b11-copd-3-797]).

Age is an important issue to be considered; the increasing duration of life in the general population and the increasing life expectancy in COPD patients due to LTOT make common to find elder patients with severe ARF in ER. In these patients, the balance for ETI---as assessed by the ER physician---is often critical, leaving NIMV as the only treatment option.

The present study, that included elderly patients (mean age of 81 years) with acute-on-chronic respiratory failure (all patients were on LTOT), shows a low mortality rate (about 13%), that is particularly favourable in this setting. In fact previous studies reported the older age as a predictor of NIMV failure in patients with ARF ([@b4-copd-3-797]). Also in our study age was a critical factor, since the mean age of the NIMV-nonresponders was significantly higher compared to that of the responders (87.4 years versus 80.5 years). Regardless the age, other studies on COPD patients with DNI status reported a mortality rate of 34%--43% ([@b20-copd-3-797]; [@b26-copd-3-797]; [@b14-copd-3-797]).

In our study, the small number of subjects who failed to respond to NIMV---eight, with seven deaths and one patient undergoing ETI successfully---did not allow us to use the best analysis in evaluating risk factors, ie, odds ratio and 95% confidence interval. Some findings although emerge with the simpler analysis used.

Firstly, the severe clinical conditions of patients, defined by a significantly worse score both to GCS and APACHE 2, in patients who failed to respond to NIMV, confirms previous observations obtained with the same parameters ([@b9-copd-3-797]; Phua et al 2006) or using other severity-of-illness classification, as the Simplified Acute Physiology Score or the Logistic Organ Dysfunction ([@b4-copd-3-797]; [@b11-copd-3-797]). In particular, a GCS lower than 11 and an APACHE II score higher than 29 were found to predict a failure risk of NIMV in patients with COPD exacerbation ([@b24-copd-3-797]). Moreover, a high APACHE II score proved to predict NIMV failure in hypercapnic ARF due both to COPD and non-COPD conditions ([@b8-copd-3-797]). Such data agree with our findings, obtained in COPD patients but also with other conditions underlying ARF.

Concerning functional parameters, baseline ratio of PaO~2~/FiO~2~ was not significantly different in successful NIMV compared with unsuccessful NIMV. Also baseline PaCO~2~ was not significantly higher in unsuccessful than in successful NIMV, while the difference in mean value was close to significance after 1 hour (p = 0.052) and significant after 12 hours of NIMV (p = 0.003). Indeed, the pH value is the major parameter that indicates the need of ventilation in ARF patients ([@b8-copd-3-797]) and in our population pH mean value was significantly lower in the failure group than in successful one, both after 1 hour (p \< 0.001) and after 12 hours of NIMV (p = 0.01). In the study by [@b9-copd-3-797] a pH value \< 7.25 increased by more than 90% the risk of failure of NIMV. This disagrees with our data, since most of our successfully treated patients had a pH lower than 7.25. However, that study included only COPD exacerbations, while our patients had also different underlying diseases, that make the comparison not completely appropriate. The intra-group analysis of our patients showed a significant improvement of pH and PaCO~2~ only in successfully treated subjects, but the overlapping between the two groups in physiological parameters makes difficult to predict the response to NIMV in this kind of patients. Thus, the baseline severity of the clinical status appears to be the most important factor in influencing the outcome.

In the 54 NIMV-responders a rapid clinical improvement was achieved, allowing their discharge after about two weeks of hospitalization. Such findings offer some outlook about the need "to evaluate the clinical outcomes of using noninvasive positive pressure ventilation for patients who choose to forego endotracheal intubation and to examine the perspectives of patients, families, and clinicians on use of NPPV in these contexts" ([@b10-copd-3-797]). Moreover, NIMV may improve the end of life care in advanced COPD, where there is evidence of unmet needs ([@b27-copd-3-797]).

In conclusion, this study shows that elderly patients with ARF from COPD exacerbations (but also from other respiratory disorders) and with a DNI status can be successfully treated by NIMV.
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###### 

Characteristics of patients at admittance

  Parameter                 Mean value (SD)
  ------------------------- -----------------
  GCS                       11.1 ± 3.5
  APACHE 2 score            27.2 ± 5.8
  PaO~2~                    49.0 ± 16.5
  PaCO~2~                   85.6 ± 18.0
  pH                        7.23 ± 0.09
  HCO~3~                    35.6 ± 6.5
  FiO~2~                    0.28 ± 0.1
  Respiratory rate          31.9 ± 8.6
  Heart rate                99.3 ± 22.2
  Systolic blood pressure   98.8 ± 21.5

**Abbreviations:** GCS, glasgow coma score; SD, standard deviation.

###### 

Difference in considered parameters in successful and unsuccessful NIMV

                                 Successful NIMV   Unsuccessful NIMV                                          Significance (p)
  ------------------------------ ----------------- ---------------------------------------------------------- ------------------
  Mean age (years)               80.46 ± 4.61      84.75 ± 4.30                                               0.016
  GCS                            11.46 ±3.23       8.12 ± 3.87                                                0.01
  APACHE 2 score                 26.62 ± 5.48      31.75 ± 6.14                                               0.018
  PaO~2~/FiO~2~                  178.96 ± 42.82    164.13 ± 54.47                                             n.s.
  PaO~2~/FiO~2~ after 1 hour     155.68± 52.29     166.88 ± 49.32                                             n.s.
  PaO~2~/FiO~2~ after 12 hours   174.33± 64.79     161.14 ± 64.54                                             n.s.
  PaCO~2~                        84.77 ± 14.45     92.75 ± 35.48                                              n.s.
  PaCO~2~ after 1 hour           70.19 ± 12.19     81.50±28.03                                                n.s. (0.052)
  PaCO~2~ after 12 hours         58.10 ± 9.02      73.28 ± 26.77[\*](#tfn3-copd-3-797){ref-type="table-fn"}   0.003
  pH                             7.24 ± 0.08       7.18 ± 0.16                                                n.s.
  pH after 1 hour                7.32 ± 0.05       7.21 ± 0.15                                                \<0.001
  pH after 12 hours              7.40 ± 0.06       7.33 ± 0.09[\*](#tfn3-copd-3-797){ref-type="table-fn"}     0.01
  HCO~3~                         35.96± 6.31       33.64 ± 7.74                                               n.s.
  HCO~3~ after 1 hour            35.37± 5.97       33.04 ± 8.43                                               n.s.
  HCO~3~ after 12 hours          34.95± 4.41       34.86 ± 9.12                                               n.s.

**Abbreviations:** GCS, glasgow coma score; NIMV, noninvasive mechanical ventilation.

**Note:** One patient died before 12 hours and is not considered here.
